Limited efficacy of lamivudine against hepatitis B virus infection in allogeneic hematopoietic stem cell transplant recipients.
BACKGROUND
Reactivation of chronic hepatitis B virus (HBV) infection is a major complication when HBV carriers receive immunosuppressive therapy. Recipients of allogeneic hematopoietic stem cell transplantation (HSCT) carry the highest risk of fatal HBV disease (up to 12%).


METHODS
In an attempt to identify a suitable procedure for the prevention and management of HBV reactivation, the administration of lamivudine over the course was tested in two patients.


RESULTS
Generally, the patients transplant courses were successfully managed despite their difficult clinical situations: a high HBV load before transplant in one patient and intense steroid therapy for complicated acute graft-versus-host disease (GVHD) in the other patient. However, one patient showed a reactivation of HBV after discontinuing lamivudine and the other showed persistently high DNA polymerase activity despite prolonged administration of lamivudine.


CONCLUSIONS
We concluded that lamivudine could have a place in the management of patients who suffer from chronic HBV infection and who are undergoing allogeneic HSCT. However, the efficacy of lamivudine seemed to be limited compared with other settings, including solid organ transplantation and autologous HSCT.
Ohnishi
Mutsuko
M
Stem Cell Transplant Unit, and Hematology Division, National Cancer Center Hospital, Tokyo 104-0045, Japan.
Kanda
Yoshinobu
Y
Takeuchi
Toshio
T
Won Kim
Sung
S
Hori
Akiko
A
Niiya
Hironari
H
Chizuka
Aki
A
Nakai
Kunihisa
K
Saito
Takeshi
T
Makimoto
Atsushi
A
Tanosaki
Ryuji
R
Watanabe
Takashi
T
Kobayashi
Yukio
Y
Tobinai
Kensei
K
Takaue
Yoichi
Y
Mineishi
Shin
S
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D001853:Bone Marrow / Q000187:drug effects; D004279:DNA, Viral / Q000097:blood; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000009:adverse effects / Q000627:therapeutic use*; D014184:Transplantation, Homologous
D000998:Antiviral Agents; D004279:DNA, Viral; D019259:Lamivudine